A Phase 1 Study of CLN-619 Alone and With Pembrolizumab Immunotherapy in People With Advanced Cervical or Endometrial Cancer


Full Title

A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors


Researchers want to find the best dose of CLN-619 for the treatment of people with advanced cervical or endometrial cancer. CLN-619 will be assessed alone and with pembrolizumab immunotherapy. The people in this study have cervical or endometrial cancer that keeps growing or came back after treatment.

CLN-619 targets cells that play a role in cancer growth. By destroying these cells, CLN-619 may help slow or stop the growth of cancer. Both CLN-619 and pembrolizumab are given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have cervical or endometrial cancer that has spread or cannot be removed with surgery and keeps growing even with treatment.
  • Have recovered from the serious side effects of prior therapies before getting the study treatment.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Vicky Makker’s office at 646-888-4224.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID